1: Ohtaki K, Matsubara K, Fujimaru S, Shimizu K, Awaya T, Suno M, Chiba K, Hayase N, Shiono H. Cefoselis, a beta-lactam antibiotic, easily penetrates the blood-brain barrier and causes seizure independently by glutamate release. J Neural Transm (Vienna). 2004 Dec;111(12):1523-35. doi: 10.1007/s00702-004-0177-0. Epub 2004 Jul 7. PMID: 15565489.
2: Zalewski P, Skibiński R, Talaczyńska A, Paczkowska M, Garbacki P, Cielecka- Piontek J. Stability studies of cefoselis sulfate in the solid state. J Pharm Biomed Anal. 2015 Oct 10;114:222-6. doi: 10.1016/j.jpba.2015.05.033. Epub 2015 Jun 1. PMID: 26073113.
3: Liu YB, Lv XJ, Yu RJ, Qiu HM, Bai JL, Jiang N, Lin JM, Liu YJ, Yan HY, Song SD, He P, Guo DY, Li XS. Multicenter, double-blind, randomized clinical trial of parenterally administered Cefoselis versus Cefepime for the treatment of acute bacterial infections. Eur Rev Med Pharmacol Sci. 2014;18(14):2006-12. PMID: 25027339.
4: Yamazaki S, Mochizuki Y, Terai T, Sugimoto M, Uchida I, Matsuoka N, Mutoh S. Intracerebroventricular injection of the antibiotic cefoselis produces convulsion in mice via inhibition of GABA receptors. Pharmacol Biochem Behav. 2002 Dec;74(1):53-9. doi: 10.1016/s0091-3057(02)00947-4. PMID: 12376152.
5: Nagata M, Yasuhara M. Effect of experimental renal failure on the pharmacodynamics of cefoselis-induced seizures in rats. Biol Pharm Bull. 2001 Sep;24(9):1049-52. doi: 10.1248/bpb.24.1049. PMID: 11558567.
6: Sugimoto M, Fukami S, Kayakiri H, Yamazaki S, Matsuoka N, Uchida I, Mashimo T. The beta-lactam antibiotics, penicillin-G and cefoselis have different mechanisms and sites of action at GABA(A) receptors. Br J Pharmacol. 2002 Jan;135(2):427-32. doi: 10.1038/sj.bjp.0704496. PMID: 11815378; PMCID: PMC1573156.
7: Cheng JW, Su JR, Xiao M, Yu SY, Zhang G, Zhang JJ, Yang Y, Duan SM, Kudinha T, Yang QW, Xu YC. In vitro Activity of a New Fourth-Generation Cephalosporin, Cefoselis, Against Clinically Important Bacterial Pathogens in China. Front Microbiol. 2020 Feb 28;11:180. doi: 10.3389/fmicb.2020.00180. PMID: 32184764; PMCID: PMC7058541.
8: Chimura T, Hirayama T, Morisaki N, Murayama K, Sato F, Akatsuka K, Numazaki M, Igarashi Y. [Clinical effects of cefoselis (CFSL) on infections in obstetric and gynecologic field and prevention of postoperative infections]. Jpn J Antibiot. 2000 Nov;53(11):637-41. Japanese. PMID: 11211699.
9: King A, Bethune L, Phillips I. The Comparative In Vitro Activity of FK-037 (Cefoselis), a New Broad-Spectrum Cephalosporin. Clin Microbiol Infect. 1995 Sep;1(1):13-17. doi: 10.1111/j.1469-0691.1995.tb00018.x. PMID: 11866715.
10: Giamarellos-Bourboulis EJ, Grecka P, Tsitsika A, Tympanidou C, Giamarellou H. In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates. Diagn Microbiol Infect Dis. 2000 Mar;36(3):185-91. doi: 10.1016/s0732-8893(99)00131-5. PMID: 10729661.